<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01294280</url>
  </required_header>
  <id_info>
    <org_study_id>CALGB-150802</org_study_id>
    <secondary_id>CDR0000600208</secondary_id>
    <secondary_id>U10CA031946</secondary_id>
    <secondary_id>NCI-2009-00454</secondary_id>
    <nct_id>NCT01294280</nct_id>
  </id_info>
  <brief_title>Biomarkers in Predicting Response in Patients With Early-Stage Non-Small Cell Lung Cancer Previously Treated With Adjuvant Chemotherapy</brief_title>
  <official_title>Participation in the Lung Adjuvant Cisplatin Evaluation Biological Program (LACE-BIO). A Study of Prognostic and Predictive Markers in Early Stage Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alliance for Clinical Trials in Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Alliance for Clinical Trials in Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research trial studies prognostic and predictive markers in patients with early stage&#xD;
      non-small cell lung cancer receiving chemotherapy. Prognostic markers are patient or tumor&#xD;
      factors that predict patient survival independent of treatment. Predictive markers are&#xD;
      factors that may influence and predict the outcome of treatment in terms of either response&#xD;
      or survival benefit. Collecting and storing samples of tissue from patients with cancer to&#xD;
      study in the laboratory may help doctors learn more about cancer and identify biomarkers&#xD;
      related to cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Evaluate potential prognostic and predictive markers in patients receiving adjuvant&#xD;
      chemotherapy for early stage non-small cell lung cancer (NSCLC).&#xD;
&#xD;
      II. To perform cross-validation analyses for the predictive value of cyclin-dependent kinase&#xD;
      inhibitor 1B (p27), excision repair cross-complementation group 1 (ERCC1), beta-tubulin and&#xD;
      B-cell lymphoma 2 (BCL2)-associated X protein (BAX).&#xD;
&#xD;
      III. To perform cross-validation analyses for the prognostic value of mucin and breast cancer&#xD;
      (BRCA)1 expression.&#xD;
&#xD;
      IV. To perform a pooled analysis for the prognostic impact of p53 protein expression by&#xD;
      immunohistochemistry (IHC), tumor protein p53 (p53) mutation, ras mutation and epidermal&#xD;
      growth factor receptor (EGFR) mutation, and Fas cell surface death receptor (Fas)/Fas ligand&#xD;
      (FasL) expression by IHC.&#xD;
&#xD;
      V. Validation of the 15-gene prognostic and predictive messenger ribonucleic acid (mRNA)&#xD;
      signature on Lung Adjuvant Cisplatin Evaluation (LACE)-Bio formalin-fixed paraffin-embedded&#xD;
      (FFPE) tumor samples.&#xD;
&#xD;
      VI. Exploratory evaluation of the prognostic and predictive values of known potential&#xD;
      oncogenic mutations using LACE-Bio FFPE.&#xD;
&#xD;
      VII. Exploratory evaluation of the prognostic and predictive values of gene copy variation&#xD;
      using LACE-Bio FFPE tumor samples.&#xD;
&#xD;
      VIII. Exploratory identification and evaluation of prognostic and predictive value of novel&#xD;
      genomic aberrations discovered by Next Generation Sequencing on LACE-Bio tumor samples.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Previously collected tissue samples are analyzed by IHC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2008</start_date>
  <completion_date type="Actual">February 2, 2016</completion_date>
  <primary_completion_date type="Actual">February 2, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">241</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Ancillary-Correlative (IHC)</arm_group_label>
    <description>Previously collected tissue samples are analyzed by IHC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Ancillary-Correlative (IHC)</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tissue&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients registered to Cancer and Leukemia Group B (CALGB) 9633&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Registration to CALGB9633 for this study&#xD;
&#xD;
          -  Institutional Review Board (IRB) review and approval at the institution where the&#xD;
             laboratory work will be performed is required&#xD;
&#xD;
          -  Informed consent:&#xD;
&#xD;
               -  The subject population to be studied in this protocol includes patients selected&#xD;
                  from CALGB 9633 for whom an available specimen is present at the Alliance Ohio&#xD;
                  State University (OSU); all such patients have signed a written informed consent&#xD;
                  document meeting all federal, state, and institutional guidelines as part of&#xD;
                  entry into that trial&#xD;
&#xD;
               -  Only cases with adequate tumor formalin FFPE material without depleting the&#xD;
                  available clinical block(s) are eligible&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Graziano, MD</last_name>
    <role>Study Chair</role>
    <affiliation>State University of New York - Upstate Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>February 10, 2011</study_first_submitted>
  <study_first_submitted_qc>February 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2011</study_first_posted>
  <last_update_submitted>January 19, 2021</last_update_submitted>
  <last_update_submitted_qc>January 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stage I Non-Small Cell Lung Cancer</keyword>
  <keyword>Stage II Non-Small Cell Lung Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

